Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:32 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 328 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Haemophilia A Clear all

Conditions: Hemophilia A
Interventions: NXT007, Human Coagulation Factor VIII; Combination Product · Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 12 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 2
States / cities: Aurora, Colorado • Iowa City, Iowa

Conditions: Hemophilia A
Interventions: Blood sample collection; Procedure
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 18 Years and older
Enrollment: 186 participants
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Hemophilia A With Inhibitors
Interventions: rFVIIIFc; Biological
Lead sponsor: Bioverativ, a Sanofi company; Industry
Eligibility: Male only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 12
States / cities: Orange, California • Aurora, Colorado • Washington D.C., District of Columbia + 9 more

Conditions: Congenital Hemophilia A
Interventions: rVIII-SingleChain; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: Up to 11 Years · Male only
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Aurora, Colorado • Chicago, Illinois

Conditions: Von Willebrand Disease, Blood Coagulation Disorders, Blood Platelet Disorders, Hematologic Disease
Interventions: Blood coagulation Factor VIII and vWF, human; Drug
Lead sponsor: CSL Behring; Industry
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Hemophilia A
Interventions: valoctocogene roxaparvovec; Biological
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 15
States / cities: Los Angeles, California • Sacramento, California • San Diego, California + 12 more

Conditions: Hemophilia A or B
Interventions: Not listed
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Hemophilia A
Interventions: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method, PEGylated Recombinant Factor VIII; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 12 Years to 65 Years · Male only
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 17
States / cities: Aurora, Colorado • Gainesville, Florida • Atlanta, Georgia + 14 more

Conditions: Hemophilia
Interventions: Fitusiran, Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC); Drug · Biological
Lead sponsor: Sanofi; Industry
Eligibility: 1 Year to 11 Years · Male only
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 8
States / cities: Los Angeles, California • Orange, California • Torrance, California + 4 more

Conditions: Hemophilia A
Interventions: SPK-8011QQ; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 6
States / cities: Orange, California • San Francisco, California • Vallejo, California + 3 more

Conditions: Mild Hereditary Factor VIII Deficiency Disease Without Inhibitor, Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor, Hemophilia A
Interventions: Emicizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: Not listed
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 5
States / cities: Los Angeles, California • Atlanta, Georgia • Indianapolis, Indiana + 2 more

Conditions: Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions: eptacog alfa (activated); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 16 Years and older · Male only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 4
States / cities: Berkeley, California • Los Angeles, California • Iowa City, Iowa + 1 more

Conditions: Acquired Hemophilia A
Interventions: OBI-1; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 18 Years and older
U.S. locations: 4
States / cities: Bethesda, Maryland • Boston, Massachusetts • Hershey, Pennsylvania + 1 more

Conditions: Hemophilia
Interventions: Coagulation Factor VIIa (Recombinant); Biological
Lead sponsor: Laboratoire français de Fractionnement et de Biotechnologies; Industry
Eligibility: 6 Months to 75 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Thrombosis
Interventions: Kcentra, Apixaban, Placebo; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hemophilia A
Interventions: SPK-8011, SPK-8016; Genetic
Lead sponsor: Spark Therapeutics, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2032
U.S. locations: 9
States / cities: Boston, Massachusetts • Madison, Mississippi • Kansas City, Missouri + 5 more

Conditions: Severe Hemophilia A
Interventions: rF.VIII; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older · Male only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania + 2 more

Conditions: Congenital Bleeding Disorder, Haemophilia A
Interventions: turoctocog alfa pegol; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 12 Years and older · Male only
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 31
States / cities: Phoenix, Arizona • Long Beach, California • Sacramento, California + 26 more

Conditions: Severe Hemophilia A
Interventions: Factor VIII (rFVIIIFc), Advate®; Drug
Lead sponsor: Bioverativ Therapeutics Inc.; Industry
Eligibility: 12 Years and older · Male only
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 21
States / cities: Little Rock, Arkansas • Los Angeles, California • Orange, California + 17 more

Conditions: Hemophilia, Hemophilia A, Hemophilia B, Hemophilia A With Inhibitor, Hemophilia B With Inhibitor, Haemophilia B Without Inhibitor, Haemophilia A Without Inhibitor, Haemophilia
Interventions: Not listed
Lead sponsor: American Thrombosis and Hemostasis Network; Network
Eligibility: 0 Years to 13 Years
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 27
States / cities: Phoenix, Arizona • Madera, California • San Diego, California + 24 more

Conditions: Hemophilia B
Interventions: Non-Interventional; Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 16 Years and older · Male only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 9
States / cities: Aurora, Colorado • New Haven, Connecticut • Washington D.C., District of Columbia + 6 more

Conditions: Hemophilia A, Bleeding Disorder
Interventions: Not listed
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 10 Years to 65 Years · Female only
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Hemophilia A
Interventions: BAY94-9027; Biological
Lead sponsor: Bayer; Industry
Eligibility: Up to 12 Years · Male only
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 7
States / cities: Sacramento, California • Pensacola, Florida • Cincinnati, Ohio + 4 more

Conditions: Hemophilia A
Interventions: Antihemophilic factor, recombinant, manufactured protein-free; Drug
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 10 Years and older · Male only
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 11
States / cities: Aurora, Colorado • Atlanta, Georgia • Peoria, Illinois + 7 more

Search by objective public record fields.

A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A

A Study to Evaluate Seroprevalence and Seroconversion of Antibodies to Adeno-Associated Virus (AAV) in Patients With Hemophilia A

A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)

Pharmacokinetic, Efficacy, and Safety Study of Recombinant Factor VIII Single Chain (rVIII-SingleChain) in Children With Severe Hemophilia A

Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD)

Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients (BMN 270-301)

A Study to Describe Patient REal-world FitusiRan ExpeRience

Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study)

A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B

A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A

A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors

Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of Thromboelastography

Expanded Access to B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies

LR769 in Congenital Hemophilia Patients With Inhibitors Undergoing Elective Surgery or Invasive Procedures

Reversibility of Apixaban Anticoagulation With the Four Factor Prothrombin Complex Concentrate Kcentra

Long-Term Safety and Efficacy of Spark-Sponsored Gene Therapies in Males With Hemophilia A

Hemophilia Adult Prophylaxis Study: Factor VIII in Severe Hemophilia A

Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A

Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A

ATHN 8: Previously Untreated Patients (PUPs) Matter Study

A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy

Characterizing the Impact and Treatment of Reproductive Tract Bleeding on Women and Post-menarchal Girls With Bleeding Disorders

Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A

Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901